Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi,

Slides:

Advertisements

Similar presentations

Quantitative modeling of chronic myeloid leukemia: insights from radiobiology by Tomas Radivoyevitch, Lynn Hlatky, Julian Landaw, and Rainer K. Sachs Blood.

Advertisements

ENESTnd 24-Month Update: Continued Superiority of Nilotinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Early Molecular and Cytogenic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML) Hanfstein B.

Allogeneic stem cell transplantation for adult Philadelphia chromosome–negative acute lymphocytic leukemia: comparable survival rates but different risk.

Interferon-alfa for chronic myeloid leukemia

Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Fan et al. Am J Nephrol 2017;45: (DOI: / )

Monitoring Milestones in Patients With Chronic Myeloid Leukemia

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Chronic Myelogenous Leukemia Diagnosis and Treatment

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients.

Patients’ priorities in selecting chronic lymphocytic leukemia treatments by Carol Mansfield, Anthony Masaquel, Jessie Sutphin, Elisa Weiss, Meghan Gutierrez,

by Michael F. Leahy, and J. Harvey Turner

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia by Davide Rossi, Silvia Rasi, Valeria.

Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study by Andreas K. Øvlisen, Anders Oest,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.

by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years Masatsugu Tanaka, Koichi Miyamura,

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

1Kantarjian HM et al. Lancet Oncol 2011;12:

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

Recipient PTPN22 −1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen by Haris Ali, Ibrahim Aldoss, Dongyun.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Leber B et al. Proc ASH 2013;Abstract 94.

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17 Jinichi.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine by Raphaelle Fanciullino, Laure Farnault, Mélanie.

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation by Yoshihiro Inamoto, Tomohiro Matsuda, Ken Tabuchi,

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Stavros V. Konstantinides et al. JACC 2017;69:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Kaplan-Meier survival estimates for major cardiovascular events.

Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation by Koichi Miyamura, Takuya Yamashita,

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Impact of age on clinical risk scores in follicular lymphoma

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

Kaplan-Meier analysis for the cumulative percentage of patients who remained hospitalized according to presence or absence of ARF with or without other.

Long-Term Outcome Of Acute Promyelocytic Leukemia (APL) With Lower Initial Leukocyte Counts By Using All-Trans Retinoic Acid (ATRA) Alone For Remission.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib by Chung H. Kok, David T.

Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance by Alexandra M. Stevens, Jennifer.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Cold agglutinin disease

Outcomes in patients with PTCL

Presentation transcript:

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi, Shigeki Ohtake, Noriko Usui, Chiaki Nakaseko, Hiroyuki Fujita, Shin Fujisawa, Toru Sakura, Hirokazu Okumura, Noriyoshi Iriyama, Nobuhiko Emi, Katsumichi Fujimaki, Sumihisa Honda, Yasushi Miyazaki, and Tomoki Naoe BloodAdv Volume 3(3):312-319 February 12, 2019 © 2019 by The American Society of Hematology

Koichi Miyamura et al. Blood Adv 2019;3:312-319 © 2019 by The American Society of Hematology

Design of JALSG CML207 phase 3 study. Design of JALSG CML207 phase 3 study. IM, imatinib. Koichi Miyamura et al. Blood Adv 2019;3:312-319 © 2019 by The American Society of Hematology

Molecular response. Molecular response. Rates of MR3 at 12 and 24 months. The results in the ITT population were calculated using the Cochran–Mantel–Haenszel test. Koichi Miyamura et al. Blood Adv 2019;3:312-319 © 2019 by The American Society of Hematology

Cumulative incidence of MR3. Cumulative incidence of MR3. Kaplan-Meier estimates of the time to the first MR3. All time-to-event comparisons in the ITT were performed using the log-rank test, stratified according to Sokal risk group. Solid and dashed lines indicate groups B and A, respectively. Koichi Miyamura et al. Blood Adv 2019;3:312-319 © 2019 by The American Society of Hematology

Results of dose escalation. Results of dose escalation. (A) The proportion of protocol compliance at 3 and 6 months. Patients who did not receive cytogenetic or molecular tests properly were excluded. (B) Levels of molecular remission according to dose escalation status. The left bar shows the result of 29 patients who did not need to increase at 3 months and 6 months. The middle bar represents the 42 patients who accurately increased their dose of imatinib at 3 months and 6 months in accordance with the protocol. The right bar shows the outcome in the 40 patients who failed to increase their dose of imatinib at 3 months or 6 months according to the protocol. Three patients (corresponding to the middle bar) and 5 patients (corresponding to right bar) who did not have a molecular response test at 12 months were excluded from this analysis. Koichi Miyamura et al. Blood Adv 2019;3:312-319 © 2019 by The American Society of Hematology

Rate of survival. Rate of survival. (A) OS. (B) Progression/failure-free survival. Koichi Miyamura et al. Blood Adv 2019;3:312-319 © 2019 by The American Society of Hematology